Industry News
Micro discovery nets Lasker Prize
Three researchers at the forefront of microRNA discovery receive rich Lasker Prize [ + ]
The malaria parasite, the tomato trichome and the honeybee’s knees
The September/October 2008 issue of Australian Life Scientist is out now. [ + ]
Vaccines and the world
The World Vaccines Congress is coming to Sydney next month [ + ]
Solar pioneer is scientist of the year
Engineer Martin Green has been named NSW Scientist of the Year [ + ]
NSW Scientist of the Year 2008
The NSW Scientist of the Year Awards, an initiative of the NSW government’s Department of State and Regional Development through its Office for Science and Medical Research, have been presented to nine outstanding scientists.
[ + ]Innovation review paper released
The report of the Review of Australia's National Innovation System concludes that the country is falling behind the rest of the world and includes recommendations across a number of themes including innovation in business, strengthening people and skills, excellence in national research, information and market design, and taxation.
[ + ]Full funding of public research: innovation review
Full funding of university and public sector research should be re-established, innovation review recommends [ + ]
Venturous Australia: innovation review released
R&D tax credits, pre-seed grants, full funding of university research recommended [ + ]
Peplin into Phase III
Peplin to conduct Phase III trial of PEP005 under special protocol assessment [ + ]
Coats on for Starpharma
Starpharma sells VivaGel condom marketing rights to Durex in potential $100m deal [ + ]
Bad boys hold NSW reins
Two MPs with blemished records have been named to head NSW’s health and science portfolios [ + ]
ASCC board squabble blows up
Stakeholders take over control of stem cell centre [ + ]
Board quits stem cell centre
The board of the Australian Stem Cell Centre (ASCC) is set to resign [ + ]
Spinifex gets cash for pain
Investors inject $12 million in private biotech Spinifex [ + ]
Cytopia begins Phase II
Cytopia in Phase II trials of its vascular disrupting agent CYT997 in brain cancer [ + ]